who's who

3 Houston innovators to know this week

This week's roundup of Houston innovators includes Jim Gable of Chevon, Brad Burke of Rice Alliance, and Chris Romani of illumipure. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from academia to energy tech — recently making headlines in Houston innovation.

Houston energy innovator on why now's the right time for energy transition innovation

Jim Gable, vice president of innovation at Chevron and president of Chevron Technology Ventures, joins the Houston Innovators Podcast. Photo courtesy

The cleantech innovation space has momentum, and Chevron strives to be one of the incumbent energy companies playing a role in that movement, Jim Gable, vice president of innovation at Chevron and president of Chevron Technology Ventures, shares on the Houston Innovators Podcast.

"People call it cleantech 2.0, but it's really cleantech 3.0," Gable says, explaining how he's been there for each wave of cleantech. "The people are better now — the entrepreneurs are better, the investors are better. Exits are here in the cleantech space."

"It's all driven by policy-enabled markets, and the policy is here now too. Twenty years ago, you didn't have nearly the same level of policy influence that you do now," he continues. "Things are coming together to help us really create and deliver that affordable, reliable, ever cleaner energy that's going to be needed for a long time." Read more.

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship

Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, has received an impressive award for his leadership. Photo via Rice.edu

A figurehead in Houston's innovation ecosystem has received an award for his career leading innovation in higher education.

Brad Burke, who's served as managing director of the Rice Alliance for Technology and Entrepreneurship since its inception 22 years ago, received the Outstanding Contributions to Advancing Innovation and Entrepreneurship in Higher Education Award. Burke was presented with the award at the 2023 Deshpande Symposium for Innovation and Entrepreneurship in Higher Education.

Recognizing an individual who has proven to be successful in leading entrepreneurship within higher education, the award was founded by serial entrepreneur Desh Deshpande. The event attracts academics, policy planners, and practitioners every year to share thought leadership within higher education entrepreneurship and innovation. Read more.

Chris Romani, chief marketing officer for illumiPure

If mobile marketing isn't in your startup's toolkit, it should be. Photo courtesy

When it comes to marketing tools, there's a lot out there. Some aren't worth it, but some can make a huge difference. Chris Romani, chief marketing officer for illumiPure, Houston-based medical device company, in a guest column for InnovationMap, outlined some of the tools that make an impact.

"For startups, when and how to begin marketing their business can feel like a cumbersome task," he explains. "As a chief marketing officer, I was asked to list services and channels that I oversee, and I came up with 16. For founders of startups who must often take on the roles of CEO and COO in addition to CMO as they look to expand their teams, that time commitment is not reasonable for someone who also has a personal life." Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted